Beijing Immunochina Medical Science & Technology Co., Ltd.
Beijing Immunochina Medical Science & Technology Co., Ltd.
Explore linked clinical trials.7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction | Adenocarcinoma of Esophagogastric Junction; Adenocarcinoma of Gastric | Not yet recruiting | Phase 1 | 2026-02-13 | NCT07406984 | |
| Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus | Difficult to Treat Systemic Lupus Erythematosus | Not yet recruiting | Early phase 1 | 2025-03-24 | NCT06886919 | |
| Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Not yet recruiting | Phase 1 | 2025-02-28 | NCT06852573 | |
| Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 | 2024-12-05 | NCT06718738 | |
| IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, membranous glomerulonephritis, nephritis, urinary system disorder | Not yet recruiting | Early phase 1 | 2024-11-26 | NCT06690359 | |
| WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Not yet recruiting | Early phase 1 | 2024-11-18 | NCT06691308 | |
| Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients | non-Hodgkin lymphoma | Recruiting | Phase 1 / Phase 2 | 2020-12-08 | NCT04440436 |